Patent classifications
A61K31/345
Small organic molecules for use in the treatment of neuroinflammatory disorders
This invention provides small organic molecules useful as therapeutics of neurodegenerative diseases. Small organic molecules that act as inhibitors of bone morphogenetic proteins (BMPs) are useful in the treatment of neuroinflammatory disorders, in particular multiple sclerosis.
Small organic molecules for use in the treatment of neuroinflammatory disorders
This invention provides small organic molecules useful as therapeutics of neurodegenerative diseases. Small organic molecules that act as inhibitors of bone morphogenetic proteins (BMPs) are useful in the treatment of neuroinflammatory disorders, in particular multiple sclerosis.
METHOD TO PREVENT AND TREAT MACULAR DEGENERATION BY CALCIUM CHANNEL BLOCKERS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS, AND ANGIOTENSIN RECEPTOR BLOCKERS
A method is provided to prevent and to treat Macular Degeneration by using Calcium Channel Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors, or Angiotensin Receptor Blockers (ARB), and more particularly, to a method to prevent and treat Macular Degeneration by using Calcium Channel Blockers, Angiotensin-Converting Enzyme Inhibitors, or Angiotensin Receptor Blockers that are not taken orally, but administered by ophthalmic preparation directly onto or into the eye where Macular Degeneration is formed, to increase the capillary network and blood supply to the retinal macula.
METHOD TO PREVENT AND TREAT MACULAR DEGENERATION BY CALCIUM CHANNEL BLOCKERS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS, AND ANGIOTENSIN RECEPTOR BLOCKERS
A method is provided to prevent and to treat Macular Degeneration by using Calcium Channel Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors, or Angiotensin Receptor Blockers (ARB), and more particularly, to a method to prevent and treat Macular Degeneration by using Calcium Channel Blockers, Angiotensin-Converting Enzyme Inhibitors, or Angiotensin Receptor Blockers that are not taken orally, but administered by ophthalmic preparation directly onto or into the eye where Macular Degeneration is formed, to increase the capillary network and blood supply to the retinal macula.
Brominated furanone derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient
The present invention relates to a novel brominated furanone derivative, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient, wherein the novel brominated furanone derivative or a pharmaceutically acceptable 5 salt thereof according to the present invention exhibits a quorum sensing inhibitory activity of bacteria and also can effectively inhibit the formation of biofilm of bacteria, and thus can be used as a pharmaceutical composition containing the same as an active ingredient, thereby having an effect of being useful, 10 for example, for periodontal diseases such as gingivitis and periodontitis, oral diseases, and the like.
AGENT FOR ENHANCING SKIN BARRIER, MEDICINAL COMPOSITION, MEDICATED COSMETIC, AND BEAUTY CARE METHOD
An agent for enhancing the skin barrier that can enhance skin barrier functions is provided. The agent for enhancing the skin barrier, including at least one of a monosaccharide and a sugar alcohol, in which a pH is 4.0 to 7.0 is provided.
AGENT FOR ENHANCING SKIN BARRIER, MEDICINAL COMPOSITION, MEDICATED COSMETIC, AND BEAUTY CARE METHOD
An agent for enhancing the skin barrier that can enhance skin barrier functions is provided. The agent for enhancing the skin barrier, including at least one of a monosaccharide and a sugar alcohol, in which a pH is 4.0 to 7.0 is provided.
Detecting and treating growth hormone deficiency
Described herein is a new oral method for using MK-0677 for detecting growth hormone (GH) deficiency (GHD). Also described is a method of treating growth hormone (GH) deficiency (GHD) in children with a functional hypothalamic-pituitary GH axis.
COMBINATION OF A UBIQUITIN-CONJUGATING ENZYME COMPLEX INHIBITOR AND ANTIHYPERTENSIVE AND/OR HYPOGLYCEMIC DRUGS IN DIABETIC KIDNEY DISEASE
The present invention relates to a composition comprising at least one inhibitor of the enzymatic complex conjugating ubiquitin Ubc13/Uev1a and at least one anti-hypertensive agent inhibiting the renin-angiotensin-aldosterone system and/or a hypoglycemic agent. Medical uses and pharmaceutical compositions comprising this composition also fall within the scope of the present invention. In particular, this composition can be used for the treatment or prevention of the renal fibrotic damage, in particular in patients suffering from diabetes.
COMBINATION OF A UBIQUITIN-CONJUGATING ENZYME COMPLEX INHIBITOR AND ANTIHYPERTENSIVE AND/OR HYPOGLYCEMIC DRUGS IN DIABETIC KIDNEY DISEASE
The present invention relates to a composition comprising at least one inhibitor of the enzymatic complex conjugating ubiquitin Ubc13/Uev1a and at least one anti-hypertensive agent inhibiting the renin-angiotensin-aldosterone system and/or a hypoglycemic agent. Medical uses and pharmaceutical compositions comprising this composition also fall within the scope of the present invention. In particular, this composition can be used for the treatment or prevention of the renal fibrotic damage, in particular in patients suffering from diabetes.